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1607-551X/Copyright ª 2015, KaohsiuAbstract Eukaryotic organisms require oxygen homeostasis to maintain proper cellular func-
tion for survival. During conditions of low oxygen tension (hypoxia), cells activate the tran-
scription of genes that induce an adaptive response, which supplies oxygen to tissues.
Hypoxia and hypoxia-inducible factors (HIFs) may contribute to the maintenance of putative
cancer stem cells, which can continue self-renewal indefinitely and express stemness genes
in hypoxic stress environments (stem cell niches). Reactive oxygen species (ROS) have long
been recognized as toxic by-products of aerobic metabolism that are harmful to living cells,
leading to DNA damage, senescence, or cell death. HIFs may promote a cancer stem cell state,
whereas the loss of HIFs induces the production of cellular ROS and activation of proteins p53
and p16Ink4a, which lead to tumor cell death and senescence. ROS seem to inhibit HIF regula-
tion in cancer cells. By contrast, controversial data have suggested that hypoxia increases the
generation of ROS, which prevents hydroxylation of HIF proteins by inducing their transcription
as negative feedback. Moreover, hypoxic conditions enhance the generation of induced plurip-
otent stem cells (iPSCs). During reprogramming of somatic cells into a PSC state, cells attain a
metabolic state typically observed in embryonic stem cells (ESCs). ESCs and iPSCs share similar
bioenergetic metabolisms, including decreased mitochondrial number and activity, and
induced anaerobic glycolysis. This review discusses the current knowledge regarding theeclare no conflicts of interest.
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Oxygen homeostasis is essential for multicellular organisms
to maintain proper function in cellular metabolism and
bioenergetics. Oxygen deprivation creates significant stress
that induces cellular responses, which lead to the genera-
tion of new vasculature to increase oxygen supply and
glycolytic capability [1]. An appropriate stress response is
required for cells to maintain homeostasis. Low oxygen
tension (hypoxia) maintains the undifferentiated state of
embryonic, hematopoietic, mesenchymal, and neural pro-
genitor cells [2]. Because complete absence of O2 (anoxia)
results in cell death [3], cells must respond quickly to
decreasing O2 levels before reaching an anoxic state. Dur-
ing hypoxia, cells activate the transcription of genes that
induce the adaptive response to supply O2 to tissues by
angiogenesis and erythropoiesis [4]. Reactive oxygen spe-
cies (ROS), such as the superoxide anion (O2
), hydrogen
peroxide (H2O2), and the hydroxyl radical (HO
), consist of
radical and nonradical oxygen species formed by the partial
reduction of oxygen. ROS have been understood to be toxic
by-products of aerobic metabolism, leading to cell damage
[5].
It seems that the most important transcription factors in
the hypoxic response are the hypoxia-inducible factors
(HIFs) [6], which mediate transcriptional response to
localized hypoxia, in both normal tissues and cancer cells.
HIFs consist of an oxygen-labile a-subunit (HIF-a) and a
stable b-subunit (HIF-b), and aryl hydrocarbon receptor
nuclear translator. There are three isoforms of HIF-a,
namely, HIF-1a, HIF-2a, and HIF-3a [4,6]. Hypoxia regulates
the undifferentiated state in various stem cell populations
[2]. HIFs directly regulate the expression of transcription
factors implicated in stem cell self-renewal and multi-
potency, and induce human embryonic stem cell (hESC)
signatures in cancer cells [7]. Hypoxia also enhances
reprogramming of fibroblasts into induced pluripotent stem
cells (iPSCs) [7].
This review highlights the current understanding of
emerging insights into the intricate roles and functions of
HIFs and ROS in tumor growth, apoptosis, and senescence,
and their roles in reprogramming cells into PSCs by
repression of tumor suppressor genes. Moreover, we will
discuss several crucial roles of the HIF signaling in the
regulation of stem cell self-renewal and its pluripotency.
Regulation of cancer development by HIFs and
ROS
It has been demonstrated that HIF-2a promotes hypoxic cell
proliferation by enhancing c-Myc transcriptional activity[8]. During oncogenesis, HIFs activate genes that induce
tumor invasion and migration [9], and the cancers can grow
from cancer stem cells, which are self-renewing tumor
cells, propagating tumors phenotypically similar to the
parental tumor [10,11]. Hypoxia and HIFs may contribute to
the maintenance of putative cancer stem cells [12].
The glycolysis and the consumption of glucose are pro-
moted primarily by HIF-1a, whereas fatty acid storage is
promoted by HIF-2a. Both factors inhibit mitochondrial
consumption and oxidation of carbon, leading to a
decreased production of adenosine triphosphate (ATP)
through oxidative phosphorylation and less ROS as a by-
product [4,13,14]. It has been known that mitochondria
plays a role in controlling ATP production through the
electron transport chain, calcium homeostasis, apoptosis,
and cell signaling [15]. Instead, ROS have been known to
increase HIF-a stability in inflammatory cells [16]. More-
over, accumulation of HIFs is the result of increased gen-
eration of ROS by nicotinamide adenine dinucleotide
phosphate (reduced) (NADPH) oxidase [17]. Therefore, it
should be important to reveal the underlying mechanisms
between regulation of HIFs and ROS production in cellular
metabolism, oncogenesis, and stem cell biology. ROS, such
as O2
, H2O2, and HO
, are implicated in the pathophysi-
ology of various diseases, including cancers [18]. The hyp-
oxic condition leads to increased ROS production using an
ROS-sensitive fluorescence resonance energy transfer
probe containing a redox-sensitive linker. Guzy et al [19]
found compelling evidence for increased H2O2 production
from mitochondria during hypoxia.
The oncogene Ras is the most highly mutated oncogene
found in human cancer cells [20]. Overexpression of Ras has
been linked to vascularization of tumors, and activated Ras
has also been associated with the production of ROS [21].
Thus, oxidative stress is assumed to play a key role in tumor
angiogenesis and cancer progression [22]. For example, ROS
generated by an NADPH oxidase has already been shown to
induce molecular markers of angiogenesis, such as vascular
endothelial growth factor-A (VEGF-A) [23]. Increased ROS
production by Ras-induced Nox1 (a member of the NADPH
oxidase family) is also required for oncogenic transformation
[24]. Interestingly, the activator protein-1 (AP-1) transcrip-
tion factor Jun D reduces the activity of an oxygen sensor in
the organism by regulating the expression of genes that
function in response to oxidative stress and H2O2metabolism
[18]. By limiting ROS generation and HIF-1a protein stability,
Jun D decreases the transcription of VEGF-A, displays anti-
angiogenic properties, and can counteract Ras-mediated
oncogenic effects. Similar results were obtained in a previ-
ous study in which c-Jun dimerization protein 2 (JDP2), a
member of the AP-1 transcription factor family, suppressed
cell proliferation during cancer progression and participated
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prevent damage to cells by oxidative stress [25].
The level of ROS is tightly controlled by an inducible
antioxidant program that responds to cellular stressors and
is regulated predominantly by Nrf2 and its repressor pro-
tein, the kelch-like Ech-associated protein 1 [26,27]. In
contrast to the acute response of Nrf2, in the steady state,
some somatic mutations cause destabilization of Nrf2 and
decrease the constitutive transcription of its target genes,
indicating that enhanced ROS detoxification and additional
Nrf2 functions may be critical for the induction of the
antioxidant response. A high glycolytic flux supports the
proliferative potential of murine ESCs [28]. Because JDP2 is
a member of the stress-induced AP-1 protein family [29],
we examined the role of JDP2 in cell proliferation, ROS
production, and antioxidant response and then identified
the JDP2 transcription factor as a cofactor that enhances
the antioxidant-responsive element (ARE) activity [30].
JDP2 bounds to ARE and regulates the ARE-mediated tran-
scription associated with the Nrf2/MafK factors. The Nrf2 is
known as a central regulator of the induction of many
antioxidant-responsive genes and genes encoding Phase II
detoxification enzymes. However, Nrf2 is not a DNA-binding
protein and the addition of Nrf2 and MafK leads to the
repression of ARE reporter genes. Therefore, the real
target molecule to enhance the ARE activity in response to
the oxidative stress remains to be identified. Thus, we
implicate that JDP2 is one of such molecules to enhance the
transcription activity of ARE reporter genes and to inhibit
ROS production to form the positive complex with Nrf2/
MafK via leucine zipper domains. Therefore, JDP2 acts not
only as an AP-1 repressor protein, to suppress cell prolif-
eration and induce cellular senescence during cancer pro-
gression, but also participates in the maintenance of ROS
homeostasis to prevent cell damage by ROS to maintain the
stemness feature [30]. This complex feature of JDP2 is also
controlled by hypoxia and HIFs.
Tumor hypoxia is typically associated with poor patient
prognosis, partly because low oxygen levels reduce the
effectiveness of radiation therapy, which kills tumors by
generating ROS [6]. It remains to be clarified whether
mitochondrial ROS would activate HIF-1a, which as a
feedback mechanism would decrease excessive ROS gen-
eration through the expression of cytochrome c oxidase
subunit 4 isoform 2 and glycolytic enzyme activity of py-
ruvate dehydrogenase kinase 1 (PDK1) [31]. HIF activation
might prevent excessive ROS production in hypoxic cells by
regulating mitochondrial respiration through increased
expression of PDK1 and switching of cytochrome c oxidase
subunit 4 isoform 14 [32,33]. Under normal oxygen condi-
tions (normoxia; defined as 21% O2), the HIF-a subunit is
hydroxylated at conserved proline residues in the oxygen-
dependent degradation domain by prolyl hydroxylases
(PHDs) [31].
Recent data also demonstrated that the self-renewal
state of human iPSCs may be supported by glycolysis
metabolism [34] and by mitochondrial properties similar to
those of ESCs, including low mitochondria DNA copy
number, immature organelle shape with underdeveloped
cristae, and low levels of oxidative stress [35]. Underde-
veloped mitochondrial networks and low mitochondrial
activity are common indicators of stem cell competence,as reported for primordial germ cells, early embryos, ESCs
[36], and iPSCs [35]. Glycolysis might be advantageous
compared with mitochondrial respiration, because it pro-
vides quick energy supplies, thereby avoiding toxic ROS
generation [34]. Solid tumor cells shift from aerobic
respiration to glycolysis-based metabolisms as a result of
the so-called Warburg effect [37]. It has been demon-
strated that hypoxic culture conditions and reduced
mitochondrial activity are associated with reduced ESC
differentiation and increased generation of iPSCs [38].
Thus, a hypoxic environment and glycolytic metabolism
seem to be advantageous for maintaining the stem cell
phenotype.Roles of HIFs in stemness maintenance and
cancer progression
It has been demonstrated that HIF-2a suppresses p53 tumor
suppressor protein and thereby promotes radioresistance
and chemoresistance of tumor cells [39]. Furthermore, HIF-
2a has been shown to activate Oct4, and HIF-2a-deficient
embryos have a severely reduced number of primordial
germ cells [40]. Hypoxia probably regulates the prolifera-
tion and differentiation of multiple stem cell populations
[6]; low oxygen levels are beneficial for hESCs [6], neural
stem cells [41], hematopoietic stem cells [42], and tumor
cells [43]. For example, Oct4 and c-Myc, which are the
factors identified by Takahashi and Yamanaka [44] for
generating iPSCs from differentiated cells, are activated by
HIF-2a in a renal carcinoma cell line [45]. Therefore, it is
important to determine whether HIFs are required for the
acquisition of stem cell fates, and in the mechanism un-
derlying the low oxygen effect in reprogramming of cells
[7]. Virus-mediated transduction of Yamanaka factors into
cells is now a commonly used method for generating iPSCs
[46]. Indeed, a virus infection-induced immune response,
such as innate immunity, can result in accumulation of ROS
[47]. Therefore, it was recently proposed that a virus
infection might be detrimental to the survival of iPSCs
because of ROS production [48]. It is also worthwhile con-
firming a role for ROS in reprogramming via HIF-signaling
pathways.
Hypoxia can promote an undifferentiated state in
certain populations of iPSCs and cancer progenitor cells [6].
Recent studies have suggested that during iPSC formation, a
metabolic switch from aerobic respiration and higher
mitochondrial activity to decreased mitochondrial activity
and the induction of anaerobic glycolysis needs to take
place [49]. The dependency of stem cells on glycolysis to
produce ATP could be an adaptation to hypoxic conditions
in vivo, given that low oxygen tensions seem to be a key
feature of the stem cell niche [50]. In addition, HIFs have
stage-specific roles during reprogramming of human cells
into PSCs [7], and HIF-2a is required during the early iPSC
reprogramming process for metabolic switching in human
fibroblasts. It has been proposed that the cells undergoing
the reprogramming process might have similar character-
istics to cells undergoing the progression to aggressive
tumor cells. It is worthwhile discussing how these results
add an important new perspective to our traditional view of
hypoxia, cancer, and PSCs.
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Stem cells were reported to engage scavenger antioxidant
enzymatic systems to eliminate the ROS that are regulated
by hypoxic niches and several transcription factors,
including Nrf2 and the forkhead homeobox type O (FoxO),
that activate the transcription of antioxidant enzymes [51].
In addition, stem cells can control oxidative stress to
maintain antioxidation (redox homeostasis) through mech-
anisms whereby they upregulate their own antioxidant
systems. Ataxia telangiectasia mutated (ATM) protein ki-
nase may control the intracellular levels of ROS [51]. For
example, Atm knockout mice were found to have pro-
gressive bone marrow failure, caused by a defect in he-
matopoietic stem cell function, which was associated with
elevated ROS [52]. Moreover, Atm knockout neural stem
cells were impaired by intrinsic elevation of ROS levels
[53]. Therefore, those experiments imply that the self-
renewal capability of stem cells depends on ATM-
mediated redox homeostasis [5]. The signaling of hypoxiaFigure 1. Schematic model showing regulatory mechanism of mit
factor (HIF) in tumor angiogenesis. Under normoxic condition, pr
inhibited by mitochondrial ROS. PHDs and factor inhibiting HIF (
regulated by sirtuin 3 [85], whereas HIF-a activity is upregulated
conditions, low ROS levels are maintained by redox homeostasis, w
through the activity of FoxOs, Ref1, Nrf2, and ataxia telangiectasia
HIF target genes, such as vascular endothelial growth factor (VEGF
angiogenesis, redox homeostasis.affects the crucial pathways, such as bone morphogenetic
proteins, Akt/mammalian target of rapamycin, and Notch
[4]. Medulloblastoma (MDB) precursor cells probably
require hypoxic conditions for in vitro development,
whereas exposure to 20% oxygen induces tumor cell dif-
ferentiation and cell death through inhibition of Notch
signaling. Moreover, MDB tumor cells undergo neuronal
differentiation when treated with g-secretase inhibitor,
which prevents Notch activation [54]. These results suggest
that hypoxia modulates Notch signaling in promoting the
survival and development of MDB stem cell through HIF-1a
stabilization. Studies on overexpression and knockdown of
HIF-1a and HIF-2a in the von HippeleLindau protein-
deficient clear cell renal cell carcinoma cell lines indicate
that HIF-2a, but not HIF-1a, is necessary for tumor growth
[55,56]. One possible explanation for this contradictory
effect is that HIF-1a antagonizes c-Myc function, whereas
HIF-2a promotes c-Myc activity [8].
The most advanced HIF-pathway-specific cancer drugs in
terms of therapeutic application are PHD inhibitors [4].ochondrial reactive oxygen species (ROS) and hypoxia-inducible
olyl-hydroxylase domain-containing enzymes (PHD) activity is
FIH) inhibit the expression of HIF-a subunit. HIF-a activity is
by mammalian target of rapamycin (mTOR). Under hypoxic
hich is regulated by the antioxidant enzymatic defense systems
mutated (ATM). HIF-a stabilization results in the expression of
) and erythropoietin (EPO), with effects on metabolism, tumor
Roles of HIFs and ROS in cancer and PSCs 283Xenograft tumors grown in phd2 heterozygotes are less
hypoxic and have more functional vessels than those in
control mice [57]. In addition to PHD inhibition, HIF-1a
adenoviral therapy has shown benefit in models of ischemic
disease [58] and limb ischemia in aged and diabetic mice
[59]. These findings indicate that the effects of activating
the HIF response are a part of disease recovery [4]. Future
investigation of the combined effects of HIF-targeted
therapy with ROS as an anticancer signaling agent in can-
cer cells is expected (Fig. 1). VEGF promotes the develop-
ment of increased vasculature, and is therefore an
important protein in the coordination of defense against
hypoxia [60]. In response to hypoxia, HIF-1a and HIF-2a
regulate genes that affect angiogenic changes such as those
for VEGF [61]. VEGF has become an attractive target in the
development of anticancer drugs [62]. The activity of HIF
can be induced in several transformed cells via oxygen-
independent oncogenic signaling pathways, includingFigure 2. Schematic representation of the roles of reactive
reprogramming to induced pluripotent stem cells (iPSCs) under hypo
ROS and mitochondrial (mt) DNA are high. Then, through the activa
of internal stemness genes and antioxidant enzymes increases and t
2a, and ROS signaling decrease. In the late stage of reprogramm
glycolysis. The tumor necrosis factor-related apoptosis-inducing
ATM Z ataxia telangiectasia mutated.those regulated by insulin-like growth factor 2/insulin-like
growth factor receptor, transforming growth factor-a/
epidermal growth factor receptor, and phosphoinositide 3-
kinase/Akt [63]. Moreover, JDP2 is also a target of gene
therapy for cancer because JDP2 is involved in various
functions such as senescence, cell cycle arrest, reprog-
ramming, and tumor suppression.Effects of p53 signaling on the ROS and HIF-
mediated cellular reprogramming
Inhibition of the p53 pathway increases the efficiency of
iPSC generation [64e68]. Lebedeva et al [69] reported that
the p53 null mouse and p53 knockdown human primary fi-
broblasts exhibit mitochondrial DNA depletion and mito-
chondrial mass reduction in vitro. Reduced mitochondrial
DNA levels, which have been detected in undifferentiatedoxygen species (ROS) and hypoxia-inducible factor (HIF) in
xic condition. In the early stage of reprogramming, activities of
tion of HIF-1a and HIF-2a under hypoxic conditions, expression
hat of p53 deceases. Simultaneously, activities of mt DNA, HIF-
ing to iPSCs, the metabolic switch occurs toward anaerobic
ligand (TRAIL) represses the process of iPSC reprogramming.
284 S. Saito et al.hESCs and iPSCs [55], have been linked to loss of p53 [69].
p53-depleted cells exhibit significant disruption of cellular
ROS homeostasis characterized by reduced mitochondrial
and cellular superoxide levels and increased H2O2 and ROS
levels. By contrast, ROS should be suppressed by the anti-
oxidant system (redox homeostasis) of cells during reprog-
ramming [70]. In relation to HIFs, there are opposing
effects for the binding of HIF to p53 for cell development.
For example, HIF-1a binds to p53, resulting in p53 stabili-
zation and hypoxia-induced cell death [71,72]. By contrast,
it has recently been shown that HIF-2a indirectly sup-
presses p53 activity and promotes radioresistance and
chemoresistance in cancer cells [51]. Armstrong and col-
leagues [35] emphasized the reduction in mitochondrial
mass and mitochondrial number during the reprogramming
process, which is likely to result in reduced mitochondrial
superoxide levels in human iPSCs generated by transduction
of Yamanaka 4 factors with NANOG. In addition, they found
that human iPSCs clones have antioxidant defense mecha-
nisms similar to those of hESCs, although the precise
mechanisms are unclear (Fig. 2).Conclusion
Hypoxia plays a critical role in maintaining self-renewal and
pluripotent capability in cancer and cancer stem cells.
Therefore, one can imagine that HIFs should induce dedif-
ferentiation in cancer cells as well as in normal somatic
cells. It has recently been shown that hypoxia, but not at-
mospheric oxygen (21% O2), can push differentiated hESCs
back to the stem cell state [35]. The dedifferentiation
process requires histone deacetylase (HDAC) activity
through HIFs. HIF-1a can directly interact with HDACs, and
hypoxia induces HDAC activity [73].
Reprogramming of differentiated cells to a pluripotent
state requires conversion from somatic mitochondrial-
dependent oxidative bioenergetics to glycolytic meta-
bolism [7,74]. Mitochondrial regression and deregulation of
mitochondrial DNA as a result of reprogramming of cells are
consistent with the undeveloped mitochondrial morphology
of ESCs [75,76]. iPSCs have diminished basal oxygen con-
sumption and uncoupled oxidative capacity, indicating a
shift from oxidative to glycolytic metabolism [7]. ESCs also
rely on glycolytic ATP generation, and their pluripotency is
maintained under hypoxic conditions [77]. In fact, stimu-
lation by induction of hypoxia or inhibition of the p53
pathway increased reprogramming efficiency [7,78,79].
When oxidative somatic cells are reprogrammed to become
glycolytic pluripotent cells, a metabolic change takes place
in the early stages of the reprogramming process, and HIF-
1a and HIF-2a are essential for this change [7] (Fig. 2).
The stabilization of HIF-1a and HIF-2a in fibroblasts is
not sufficient to induce pluripotency because of the
repressive effect of HIF-2a in iPSC induction through tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL).
TRAIL does not induce cell death in hESCs, cancer stem
cells, or adult somatic stem cells [7,80]. However, it is
detrimental for cancer cells [81,82] and represses the iPSC
reprogramming process [7]. Therefore, Mathieu et al [7]
suspected that cells undergoing the reprogramming pro-
cess may have similar characteristics to cells undergoingprogression toward aggressive tumor cells [7]. Further-
more, therapeutic application of iPSCs, which are gener-
ated using the reprogramming approach, with oncogenic
factors might increase the risk of tumor formation. Genetic
alterations, including copy-number variations and protein-
coding point mutations, were observed during the nor-
moxia reprogramming processes using high-resolution ge-
netic approaches [83,84]. Taken together, these findings
suggest that iPSCs have a high tumorigenic potential. In
conclusion, the common and shared distinct features of
redox homeostasis and hypoxic regulation between iPSCs
and cancer stem cells should be clarified to understand the
regulation of self-renewal, pluripotency, and cancer
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